BioPharma Dive2d
Lilly pads cancer drug pipeline with Scorpion deal
The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new ...
Eli Lilly & Co: Strong Growth Prospects and Strategic Positioning Justify Buy Rating
Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...
Hosted on MSN1d
Mounjaro and Zepbound sales disappoint, and Eli Lilly’s stock is dropping
Shares of Eli Lilly & Co. were headed for their worst day in nearly four years ... For the fourth quarter, the company said it continued to make progress on building out its manufacturing ...
Eli Lilly and Company: Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Ka inhibitor program
The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Ka inhibitor currently in a Phase 1/2 clinical trialSTX-478 ...
Eli Lilly & Co.: Positive Long-Term Outlook Despite Recent Setbacks – Buy Rating Affirmed
Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target at ...
Yahoo Finance2d
Eli Lilly and Company (LLY)
Eli Lilly and Company (NYSE: LLY) today announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, which represents growth of 32% compared to the previous year ...